Updated January 2024.
The FDA has approved several CAR-T cell therapies for the treatment of specific diseases.
These include:
- ABECMA® (idecabtagene vicleucel): Approved for adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
- Kymriah (tisagenlecleucel): Approved for B cell acute lymphoblastic leukemia in pediatric and adult patients, as well as certain B cell lymphoma subtypes, including high-grade B cell lymphoma and DLBCL that results from follicular lymphoma.
- Yescarta (axicabtagene ciloleucel): Approved for certain types of large B cell lymphoma, including diffuse large B cell lymphoma (DLBCL), primary mediastinal large B cell lymphoma, high-grade B cell lymphoma, and DLBCL that results from follicular lymphoma
- Tecartus (brexucabtagene autoleucel): Approved for adult patients with mantle cell lymphoma.
- Breyanzi (lisocabtagene maraleucel): Approved for certain types of large B cell lymphoma, including diffuse large B cell lymphoma (DLBCL), high-grade B cell lymphoma, and DLBCL that results from follicular lymphoma.
- Carvykti (ciltacabtagene autoleucel): Approved for adult patients with certain types of large B cell lymphoma, including diffuse large B cell lymphoma (DLBCL), high-grade B cell lymphoma, and DLBCL that results from follicular lymphoma.
Each therapy is approved for specific types of cancer, and the details of their approval can be found in the respective prescribing information and FDA approvals. These CAR-T cell therapies have shown promising results in the treatment of these diseases, but they can also be associated with side effects and require specialized management and monitoring.
Sources:
